Literature DB >> 7840352

Severity of symptoms in chronically institutionalized geriatric schizophrenic patients.

M Davidson1, P D Harvey, P Powchik, M Parrella, L White, H Y Knobler, M F Losonczy, R S Keefe, S Katz, E Frecska.   

Abstract

OBJECTIVE: The goal of this study was to characterize the symptoms of geriatric, chronically ill, institutionalized schizophrenic patients and investigate age-related differences in schizophrenic symptoms and cognitive performance from early adulthood to late senescence.
METHOD: The Positive and Negative Syndrome Scale and the Mini-Mental State examination were used to assess the schizophrenic symptoms and cognitive performance, respectively, of 393 institutionalized schizophrenic patients stratified into seven groups designated by 10-year age intervals from 25 years to over 85 years.
RESULTS: In the comparisons of the seven age groups, significant differences between groups in positive and negative subscale scores on the Positive and Negative Syndrome Scale and in Mini-Mental State scores were revealed. Significant correlations between Mini-Mental State scores and Positive and Negative Syndrome Scale negative symptom scores, but not positive symptom scores, were found for all age groups, except for the youngest patients studied. Current treatment with neuroleptics and prior treatment with ECT, insulin coma, or leukotomy could not account for the poor cognitive performance of the older schizophrenic patients.
CONCLUSIONS: The older schizophrenic patients continued to experience psychotic and nonpsychotic symptoms in senescence. Their positive symptoms were moderately less severe and their negative symptoms and cognitive impairment were significantly more severe than those of the younger patients. Somatic treatment appeared not to be responsible for the severe cognitive impairment and negative symptoms of the older patients. These data are relevant to chronically hospitalized geriatric schizophrenic patients but not necessarily to all geriatric schizophrenic patients.

Entities:  

Mesh:

Year:  1995        PMID: 7840352     DOI: 10.1176/ajp.152.2.197

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  35 in total

1.  Cranial MR imaging of sequelae of prefrontal lobotomy.

Authors:  A Uchino; A Kato; T Yuzuriha; Y Takashima; S Kudo
Journal:  AJNR Am J Neuroradiol       Date:  2001-02       Impact factor: 3.825

2.  Astrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophrenia.

Authors:  Pavel Katsel; William Byne; Panos Roussos; Weilun Tan; Larry Siever; Vahram Haroutunian
Journal:  Neuropsychopharmacology       Date:  2011-01-26       Impact factor: 7.853

Review 3.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

Review 4.  Very poor outcome schizophrenia: clinical and neuroimaging aspects.

Authors:  Serge A Mitelman; Monte S Buchsbaum
Journal:  Int Rev Psychiatry       Date:  2007-08

5.  Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia.

Authors:  Robert E McCullumsmith; Daya Gupta; Monica Beneyto; Emily Kreger; Vahram Haroutunian; Kenneth L Davis; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2007-01-12       Impact factor: 4.939

6.  Brodmann area analysis of white matter anisotropy and age in schizophrenia.

Authors:  Jason S Schneiderman; Erin A Hazlett; King-Wai Chu; Jane Zhang; Chelain R Goodman; Randall E Newmark; Yuliya Torosjan; Emily L Canfield; Jonathan Entis; Vivian Mitropoulou; Cheuk Y Tang; Joseph Friedman; Monte S Buchsbaum
Journal:  Schizophr Res       Date:  2011-05-19       Impact factor: 4.939

Review 7.  Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review.

Authors:  Jun Ku Chung; Shinichiro Nakajima; Eric Plitman; Yusuke Iwata; Danielle Uy; Philip Gerretsen; Fernando Caravaggio; M Mallar Chakravarty; Ariel Graff-Guerrero
Journal:  Am J Geriatr Psychiatry       Date:  2016-04-29       Impact factor: 4.105

8.  Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole.

Authors:  Izchak Kohen; Paula E Lester; Sum Lam
Journal:  Neuropsychiatr Dis Treat       Date:  2010-03-24       Impact factor: 2.570

9.  Cognitive impairment from early to middle adulthood in patients with affective and nonaffective psychotic disorders.

Authors:  Josephine Mollon; Samuel R Mathias; Emma E M Knowles; Amanda Rodrigue; Marinka M G Koenis; Godfrey D Pearlson; Abraham Reichenberg; Jennifer Barrett; Dominique Denbow; Katrina Aberizk; Molly Zatony; Russell A Poldrack; John Blangero; David C Glahn
Journal:  Psychol Med       Date:  2019-01-04       Impact factor: 7.723

10.  Identification of a serotonin/glutamate receptor complex implicated in psychosis.

Authors:  Javier González-Maeso; Rosalind L Ang; Tony Yuen; Pokman Chan; Noelia V Weisstaub; Juan F López-Giménez; Mingming Zhou; Yuuya Okawa; Luis F Callado; Graeme Milligan; Jay A Gingrich; Marta Filizola; J Javier Meana; Stuart C Sealfon
Journal:  Nature       Date:  2008-02-24       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.